Amalia Peterson1,2 | Aditi Sathe1 | Dimitrios Zaras1 | Yisu Yang1 | Alaina Durant1 | Kacie D. Deters3 | Niranjana Shashikumar1 | Kimberly R. Pechman1 | Michael E. Kim4 | Chenyu Gao5 | Nazirah Mohd Khairi5 | Zhiyuan Li5 | Tianyuan Yao4 | Yuankai Huo4,5 | Logan Dumitrescu1,2,6,7 | Katherine A. Gifford1,2 | Jo Ellen Wilson1,8,9 | Francis E. Cambronero1 | Shannon L. Risacher10,11 | Lori L. Beason-Held12 | Yang An12 | Konstantinos Arfanakis13,14,15 | Guray Erus16 | Christos Davatzikos16 | Duygu Tosun17 | Arthur W. Toga18 | Paul M. Thompson19 | Elizabeth C. Mormino20 | Mohamad Habes21 | Di Wang21 | Panpan Zhang1,22 | Kurt Schilling23,24 | Alzheimer’s Disease Neuroimaging Initiative (ADNI) | The BIOCARD | Study Team | The Alzheimer’s Disease Sequencing Project (ADSP) | Marilyn Albert25 | Walter Kukull26 | Sarah A. Biber26 | Bennett A. Landman2,4,5,7,23,24,27 | Sterling C. Johnson28,29 | Julie Schneider14 | Lisa L. Barnes14 | David A. Bennett14 | Angela L. Jefferson1,2,4 | Susan M. Resnick12 | Andrew J. Saykin10,11 | Timothy J. Hohman1,2,6,7 | Derek B. Archer1,2,6,7
Correspondence
Derek B. Archer, Vanderbilt Memory and Alzheimer’s Center, 3319 West End Ave., Nashville, TN 37203, USA. Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
Funding information
BAL, Grant/Award Number: R01-EB017230; DBA, Grant/Award Number: K01-AG073584; TJH, Grant/Award Number: U24-AG074855; Vanderbilt Clinical Translational Science Award, Grant/Award Numbers: UL1-TR000445, UL1-TR002243; Vanderbilt’s High-Performance Computer Cluster for Biomedical Research, Grant/Award Numbers: R01-AG080821, S10-OD023680; Alzheimer’s Association, Grant/Award Number: IIRG-08-88733(ALJ); NIH, Grant/Award Numbers: K01-EB032898 (KGS), R01-EB017230 (BAL), K01-AG073584 (DBA), U24-AG074855 (TJH), R01-AG059716 (TJH), UL1-TR000445 (Vanderbilt Clinical Translational Science Award), UL1-TR002243 (Vanderbilt Clinical Translational Science Award), S10-OD02380 (Vanderbilt’s High-Performance Computer Cluster for Biomedical Research), R01-AG080821 (MH), R01-AG034962 (ALJ), R01-AG056534 (ALJ), R01-AG062826 (KAG), U19-AG03655 (MA); Intramural NIH, Grant/Award Number: 75N95D22P00141
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2024 The Author(s). Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.
Abstract
INTRODUCTION: The effects of sex and apolipoprotein E (APOE)—Alzheimer’s disease (AD) risk factors—on white matter microstructure are not well characterized.
METHODS: Diffusion magnetic resonance imaging data from nine well-established longitudinal cohorts of aging were free water (FW)–corrected and harmonized. This dataset included 4741 participants (age = 73.06 ± 9.75) with 9671 imaging sessions over time. FW and FW-corrected fractional anisotropy (FAFWcorr) were used to assess differences in white matter microstructure by sex and APOE ε4 carrier status.
RESULTS: Sex differences in FAFWcorr in projection tracts and APOE ε4 differences in FW limbic and occipital transcallosal tracts were most pronounced.
DISCUSSION: There are prominent differences in white matter microstructure by sex and APOE ε4 carrier status. This work adds to our understanding of disparities in AD. Additional work to understand the etiology of these differences is warranted.
KEYWORDS
aging, Alzheimer’s disease, sex differences, white matter disease
Highlights
∙ Sex and apolipoprotein E (APOE) ε4 carrier status relate to white matter microstruc tural integrity.
∙ Females generally have lower free water–corrected fractional anisotropy compared to males.
∙ APOE ε4 carriers tended to have higher free water than non-carriers.
Michael W. Weiner1,2,3,4,5,6 | Shaveta Kanoria1,6 | Melanie J. Miller1,6 | Paul S. Aisen7 | Laurel A. Beckett8 | Catherine Conti1,6 | Adam Diaz1,6 | Derek Flenniken6 | Robert C. Green9 | Danielle J. Harvey8 | Clifford R. Jack Jr.10 | William Jagust11 | Edward B. Lee12 | John C. Morris13,14,15 | Kwangsik Nho16,17 | Rachel Nosheny1,4 | Ozioma C. Okonkwo18 | Richard J. Perrin13,14,15 | Ronald C. Petersen19 | Monica Rivera-Mindt20,21 | Andrew J. Saykin16,22 | Leslie M. Shaw23 | Arthur W. Toga24 | Duygu Tosun1,2 | Dallas P. Veitch1,6 for the Alzheimer’s Disease Neuroimaging Initiative
1 Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA
2 Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA
3 Department of Medicine, University of California San Francisco, San Francisco, California, USA
4 Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, California, USA
5 Department of Neurology, University of California San Francisco, San Francisco, California, USA
6 Northern California Institute for Research and Education (NCIRE), San Francisco, California, USA
7 Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, California, USA
8 Division of Biostatistics, Department of Public Health Sciences, University of California, Medical Sciences 1C, Davis, California, USA
9 Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Broad Institute Ariadne Labs and Harvard Medical School, Boston, Massachusetts, USA
10 Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
11 Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, USA
12 Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, Pennsylvania, USA
13 Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, Saint Louis, Missouri, USA
14 Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA
15 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA
16 Department of Radiology and Imaging Sciences and the Indiana Alzheimer’s Disease Research Center, Indiana University School of Medicine, Indianapolis, Indiana, USA
17 Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, Indiana, USA
18 Wisconsin Alzheimer’s Disease Research Center and Department of Medicine, University of Wisconsin School of Medicine and Public Health, Clinical Science Center, Madison, Wisconsin, USA
19 Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
20 Department of Psychology, Latin American and Latino Studies Institute, African and African American Studies, Fordham University, Bronx, New York, USA
21 Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
22 Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA
23 Department of Pathology and Laboratory Medicine and the PENN Alzheimer’s Disease Research Center, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
24 Laboratory of Neuro Imaging, Institute of Neuroimaging and Informatics, Keck School of Medicine of the University of Southern California, San Diego, California, USA
Michael W. Weiner, Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, 4150 Clement St, San Francisco, CA 94121, USA. Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data. Some ADNI investigators participated in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp content/uploads/how_to_apply/ ADNI_Acknowledgement_List.pd
NIH, Grant/Award Number: U19 -AG 024904; National Institute on Aging, Grant/Award Number: U19AG024904
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
The overall goal of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) is to opti mize and validate biomarkers for clinical trials while sharing all data and biofluid samples with the global scientific community. ADNI has been instrumental in stan dardizing and validating amyloid beta (Aβ) and tau positron emission tomography (PET) imaging. ADNI data were used for the US Food and Drug Administration (FDA) approval of the Fujirebio and Roche Elecsys cerebrospinal fluid diagnostic tests. Additionally, ADNI provided data for the trials of the FDA-approved treatments aducanumab, lecanemab, and donanemab. More than 6000 scientific papers have been published using ADNI data, reflecting ADNI’s promotion of open science and data sharing. Despite its enormous success, ADNI has some limitations, particularly in generalizing its data and findings to the entire US/Canadian population. This introduction provides a historical overview of ADNI and highlights its significant accomplishments and future vision to pioneer “the clinical trial of the future” focusing on demographic inclusivity.
Alzheimer’s disease, Alzheimer’s disease biomarkers, Alzheimer’s disease clinical trials, Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s disease progression, amyloid, Lab oratory of Neuro Imaging, magnetic resonance imaging, neurodegeneration, positron emission tomography, post-traumatic stress disorder, tau, underrepresented populations
∙ The Alzheimer’s Disease Neuroimaging Initiative (ADNI) introduced a novel model for public-private partnerships and data sharing.
∙ It successfully validated amyloid and Tau PET imaging, as well as CSF and plasma biomarkers, for diagnosing Alzheimer’s disease.
∙ ADNI generated and disseminated vital data for designing AD clinical trials.
现任中国医师协会烧伤科医师分会会长、中华烧伤杂志总编辑、全军烧伤外科专业委员会委员、重庆市烧伤专业委员会前任主任委员。
Authors
Deniz Harputlu
Süheyla A. Özsoy
Maarit Ahtiala
Esa Soppi
Teijo I. Saari
Keywords
Latika Rohilla
Meenakshi Agnihotri
Sukhpal Kaur Trehan
Ann N. Tescher
Susan L. Thompson
Vitaliya Boyar
quality improvement
伤口世界平台生态圈，以“关爱人间所有伤口患者”为愿景，连接、整合和拓展线上和线下的管理慢性伤口的资源，倡导远程、就近和居家管理慢性伤口，解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考，最终以医院当日公布为准。
网友、医生言论仅代表其个人观点，不代表本站同意其说法，请谨慎参阅，本站不承担由此引起的法律责任。
